Chronic pain: genes, plasticity, and phenotypes
Authors:
- Ralf BaronRBRalf Baron
- Gunnar WasnerGWGunnar Wasner
- Andreas BinderABAndreas Binder
- 1 January 2012
- journal article
- Published by Elsevier in The Lancet Neurology
- Vol. 11 (1) , 19-21
Abstract
No abstract availableFunding Information
- Allergan
- Astellas Pharma US
- Boehringer Ingelheim
- Genzyme
- Eli Lilly and Company
- Pfizer
- Novartis
This publication has 7 references indexed in Scilit:
- Engagement of descending inhibition from the rostral ventromedial medulla protects against chronic neuropathic painPain, 2011
- Efficacy and safety of tanezumab in the treatment of chronic low back painPain, 2011
- Different Pain, Different Brain: Thalamic Anatomy in Neuropathic and Non-Neuropathic Chronic Pain SyndromesThe Journal of Neuroscience, 2011
- Tanezumab for the Treatment of Pain from Osteoarthritis of the KneeNew England Journal of Medicine, 2010
- Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): Somatosensory abnormalities in 1236 patients with different neuropathic pain syndromesPain, 2010
- Thalamic atrophy associated with painful osteoarthritis of the hip is reversible after arthroplasty: A longitudinal voxel‐based morphometric studyArthritis & Rheumatism, 2010
- Gain-of-function mutation in Nav1.7 in familial erythromelalgia induces bursting of sensory neuronsBrain, 2005